Cargando…

Allogeneic Hematopoietic Stem Cell Transplantation Mobilized With Pegylated Granulocyte Colony-Stimulating Factor Ameliorates Severe Acute Graft-Versus-Host Disease Through Enrichment of Monocytic Myeloid-Derived Suppressor Cells in the Graft: A Real World Experience

We compared the effectiveness and safety of pegylated granulocyte colony-stimulating factor (peg-G-CSF) vs. non-peg-G-CSF for hematopoietic stem cell mobilization in allogeneic hematopoietic stem cell transplantation in a real-world setting. We included 136 consecutive healthy donors treated with no...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lin, Yin, Jin, Li, Yun, Wang, Chunyan, Mao, Xia, Wei, Jia, Cao, Yang, Wang, Na, Lin, Li, Xu, Jinhuan, Zhang, Yicheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072473/
https://www.ncbi.nlm.nih.gov/pubmed/33912154
http://dx.doi.org/10.3389/fimmu.2021.621935
_version_ 1783683916764282880
author Li, Lin
Yin, Jin
Li, Yun
Wang, Chunyan
Mao, Xia
Wei, Jia
Cao, Yang
Wang, Na
Lin, Li
Xu, Jinhuan
Zhang, Yicheng
author_facet Li, Lin
Yin, Jin
Li, Yun
Wang, Chunyan
Mao, Xia
Wei, Jia
Cao, Yang
Wang, Na
Lin, Li
Xu, Jinhuan
Zhang, Yicheng
author_sort Li, Lin
collection PubMed
description We compared the effectiveness and safety of pegylated granulocyte colony-stimulating factor (peg-G-CSF) vs. non-peg-G-CSF for hematopoietic stem cell mobilization in allogeneic hematopoietic stem cell transplantation in a real-world setting. We included 136 consecutive healthy donors treated with non–peg-G-CSF (n = 53) or peg-G-CSF (n = 83), and 125 consecutive recipients (n = 42 and 83, respectively) in this study. All harvesting was completed successfully. No significant difference in leukapheresis number and adverse events frequency was observed, nor were there severe adverse events leading to discontinuation of mobilization. The leukapheresis products mobilized by peg-G-CSF had higher total nucleated cells (p < 0.001), monocytic myeloid-derived suppressor cells (p < 0.001), granulocytic myeloid-derived suppressor cells (p = 0.004) and B cells (p = 0.019). CD34+ cells and other lymphocyte subsets (T cells, regulatory T cells, natural killer [NK] cells, etc.) were similar in both apheresis products. Patients who received grafts mobilized by peg-G-CSF exhibited a lower incidence of grade III-IV acute graft-versus-host disease (p = 0.001). The 1-year cumulative incidence of chronic graft-versus-host disease and relapse, 1-year probability of graft-versus-host disease-free relapse-free survival, and overall survival did not differ significantly between subgroups. Our results suggest that collecting allogeneic stem cells after the administration of peg-G-CSF is feasible and safe. Peg-G-CSF mobilized grafts may reduce severe acute graft-versus-host disease compared with non-peg-G-CSF mobilized grafts after allogeneic stem cell transplantation. The beneficial effects of a peg-G-CSF graft might be mediated by increased numbers of monocytic myeloid-derived suppressor cells.
format Online
Article
Text
id pubmed-8072473
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80724732021-04-27 Allogeneic Hematopoietic Stem Cell Transplantation Mobilized With Pegylated Granulocyte Colony-Stimulating Factor Ameliorates Severe Acute Graft-Versus-Host Disease Through Enrichment of Monocytic Myeloid-Derived Suppressor Cells in the Graft: A Real World Experience Li, Lin Yin, Jin Li, Yun Wang, Chunyan Mao, Xia Wei, Jia Cao, Yang Wang, Na Lin, Li Xu, Jinhuan Zhang, Yicheng Front Immunol Immunology We compared the effectiveness and safety of pegylated granulocyte colony-stimulating factor (peg-G-CSF) vs. non-peg-G-CSF for hematopoietic stem cell mobilization in allogeneic hematopoietic stem cell transplantation in a real-world setting. We included 136 consecutive healthy donors treated with non–peg-G-CSF (n = 53) or peg-G-CSF (n = 83), and 125 consecutive recipients (n = 42 and 83, respectively) in this study. All harvesting was completed successfully. No significant difference in leukapheresis number and adverse events frequency was observed, nor were there severe adverse events leading to discontinuation of mobilization. The leukapheresis products mobilized by peg-G-CSF had higher total nucleated cells (p < 0.001), monocytic myeloid-derived suppressor cells (p < 0.001), granulocytic myeloid-derived suppressor cells (p = 0.004) and B cells (p = 0.019). CD34+ cells and other lymphocyte subsets (T cells, regulatory T cells, natural killer [NK] cells, etc.) were similar in both apheresis products. Patients who received grafts mobilized by peg-G-CSF exhibited a lower incidence of grade III-IV acute graft-versus-host disease (p = 0.001). The 1-year cumulative incidence of chronic graft-versus-host disease and relapse, 1-year probability of graft-versus-host disease-free relapse-free survival, and overall survival did not differ significantly between subgroups. Our results suggest that collecting allogeneic stem cells after the administration of peg-G-CSF is feasible and safe. Peg-G-CSF mobilized grafts may reduce severe acute graft-versus-host disease compared with non-peg-G-CSF mobilized grafts after allogeneic stem cell transplantation. The beneficial effects of a peg-G-CSF graft might be mediated by increased numbers of monocytic myeloid-derived suppressor cells. Frontiers Media S.A. 2021-04-12 /pmc/articles/PMC8072473/ /pubmed/33912154 http://dx.doi.org/10.3389/fimmu.2021.621935 Text en Copyright © 2021 Li, Yin, Li, Wang, Mao, Wei, Cao, Wang, Lin, Xu and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Li, Lin
Yin, Jin
Li, Yun
Wang, Chunyan
Mao, Xia
Wei, Jia
Cao, Yang
Wang, Na
Lin, Li
Xu, Jinhuan
Zhang, Yicheng
Allogeneic Hematopoietic Stem Cell Transplantation Mobilized With Pegylated Granulocyte Colony-Stimulating Factor Ameliorates Severe Acute Graft-Versus-Host Disease Through Enrichment of Monocytic Myeloid-Derived Suppressor Cells in the Graft: A Real World Experience
title Allogeneic Hematopoietic Stem Cell Transplantation Mobilized With Pegylated Granulocyte Colony-Stimulating Factor Ameliorates Severe Acute Graft-Versus-Host Disease Through Enrichment of Monocytic Myeloid-Derived Suppressor Cells in the Graft: A Real World Experience
title_full Allogeneic Hematopoietic Stem Cell Transplantation Mobilized With Pegylated Granulocyte Colony-Stimulating Factor Ameliorates Severe Acute Graft-Versus-Host Disease Through Enrichment of Monocytic Myeloid-Derived Suppressor Cells in the Graft: A Real World Experience
title_fullStr Allogeneic Hematopoietic Stem Cell Transplantation Mobilized With Pegylated Granulocyte Colony-Stimulating Factor Ameliorates Severe Acute Graft-Versus-Host Disease Through Enrichment of Monocytic Myeloid-Derived Suppressor Cells in the Graft: A Real World Experience
title_full_unstemmed Allogeneic Hematopoietic Stem Cell Transplantation Mobilized With Pegylated Granulocyte Colony-Stimulating Factor Ameliorates Severe Acute Graft-Versus-Host Disease Through Enrichment of Monocytic Myeloid-Derived Suppressor Cells in the Graft: A Real World Experience
title_short Allogeneic Hematopoietic Stem Cell Transplantation Mobilized With Pegylated Granulocyte Colony-Stimulating Factor Ameliorates Severe Acute Graft-Versus-Host Disease Through Enrichment of Monocytic Myeloid-Derived Suppressor Cells in the Graft: A Real World Experience
title_sort allogeneic hematopoietic stem cell transplantation mobilized with pegylated granulocyte colony-stimulating factor ameliorates severe acute graft-versus-host disease through enrichment of monocytic myeloid-derived suppressor cells in the graft: a real world experience
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072473/
https://www.ncbi.nlm.nih.gov/pubmed/33912154
http://dx.doi.org/10.3389/fimmu.2021.621935
work_keys_str_mv AT lilin allogeneichematopoieticstemcelltransplantationmobilizedwithpegylatedgranulocytecolonystimulatingfactoramelioratessevereacutegraftversushostdiseasethroughenrichmentofmonocyticmyeloidderivedsuppressorcellsinthegraftarealworldexperience
AT yinjin allogeneichematopoieticstemcelltransplantationmobilizedwithpegylatedgranulocytecolonystimulatingfactoramelioratessevereacutegraftversushostdiseasethroughenrichmentofmonocyticmyeloidderivedsuppressorcellsinthegraftarealworldexperience
AT liyun allogeneichematopoieticstemcelltransplantationmobilizedwithpegylatedgranulocytecolonystimulatingfactoramelioratessevereacutegraftversushostdiseasethroughenrichmentofmonocyticmyeloidderivedsuppressorcellsinthegraftarealworldexperience
AT wangchunyan allogeneichematopoieticstemcelltransplantationmobilizedwithpegylatedgranulocytecolonystimulatingfactoramelioratessevereacutegraftversushostdiseasethroughenrichmentofmonocyticmyeloidderivedsuppressorcellsinthegraftarealworldexperience
AT maoxia allogeneichematopoieticstemcelltransplantationmobilizedwithpegylatedgranulocytecolonystimulatingfactoramelioratessevereacutegraftversushostdiseasethroughenrichmentofmonocyticmyeloidderivedsuppressorcellsinthegraftarealworldexperience
AT weijia allogeneichematopoieticstemcelltransplantationmobilizedwithpegylatedgranulocytecolonystimulatingfactoramelioratessevereacutegraftversushostdiseasethroughenrichmentofmonocyticmyeloidderivedsuppressorcellsinthegraftarealworldexperience
AT caoyang allogeneichematopoieticstemcelltransplantationmobilizedwithpegylatedgranulocytecolonystimulatingfactoramelioratessevereacutegraftversushostdiseasethroughenrichmentofmonocyticmyeloidderivedsuppressorcellsinthegraftarealworldexperience
AT wangna allogeneichematopoieticstemcelltransplantationmobilizedwithpegylatedgranulocytecolonystimulatingfactoramelioratessevereacutegraftversushostdiseasethroughenrichmentofmonocyticmyeloidderivedsuppressorcellsinthegraftarealworldexperience
AT linli allogeneichematopoieticstemcelltransplantationmobilizedwithpegylatedgranulocytecolonystimulatingfactoramelioratessevereacutegraftversushostdiseasethroughenrichmentofmonocyticmyeloidderivedsuppressorcellsinthegraftarealworldexperience
AT xujinhuan allogeneichematopoieticstemcelltransplantationmobilizedwithpegylatedgranulocytecolonystimulatingfactoramelioratessevereacutegraftversushostdiseasethroughenrichmentofmonocyticmyeloidderivedsuppressorcellsinthegraftarealworldexperience
AT zhangyicheng allogeneichematopoieticstemcelltransplantationmobilizedwithpegylatedgranulocytecolonystimulatingfactoramelioratessevereacutegraftversushostdiseasethroughenrichmentofmonocyticmyeloidderivedsuppressorcellsinthegraftarealworldexperience